Bicyclic compound and use thereof

A composition comprising a compound of Formula 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier:

• wherein
• X1 and X2 are each independently carbon or nitrogen;
• Y is carbon, oxygen or nitrogen;
• Z is carbon;
• n is an integer of 0 or 1;
• m is an integer of 0 to 2;
• is a single bond or a double bond;
• R1 is -D-R10;
• wherein D is a direct bond, —O—, —C(═O)—, —C≡C— or —CR11R12;
• R10 is hydrogen, halo, hydroxy, cyano, alkyl, hydroxyalkyl, haloalkyl, haloalkylsulfonate, dialkylamino, alkylaminoalkyl, dialkylaminoalkyl, dialkylaminocarbonylalkyl, saturated or unsaturated carbocyclyl, saturated or unsaturated heterocyclyl, saturated or unsaturated carbocyclyl-alkyl, or saturated or unsaturated heterocyclyl-alkyl;
• R11 and R12 are each independently hydrogen, hydroxy or alkyl;
• the carbocycle or heterocycle is optionally substituted with one or more substituents selected from hydroxy, halo, oxo, formyl (—CHO), nitrile, alkyl, alkoxy, hydroxyalkyl, hydroxyhaloalkyl, alkoxyalkyl, haloalkyl, nitrilealkyl, alkylcarbonyl, alkylthiocarbonyl, alkoxycarbonyl, haloalkylcarbonyl, carbocyclyl, carbocyclylcarbonyl, (alkyl)(haloalkyl)amino, (alkyl)(heterocyclyl)amino, heterocyclyl and heterocyclyl-alkyl;
• R2 is hydrogen or alkyl;
• R3 is hydrogen or alkyl;
• R4, R5, R6 and R7 are each independently hydrogen or alkyl;
• R8 is hydrogen, halo, alkyl, alkoxy or amino;
• and
• R9 is hydrogen, halo or alkyl;
• wherein the disease associated with PRMT5 inhibition is selected from the group consisting of cancer, blood disease, autoimmune disease, inflammatory disease and neurodegenerative disease;
• and
• wherein the composition comprises 0.5 to 100 mg/kg per day of the compound.